SAGEMCOM
15.7.2021 11:02:07 CEST | Business Wire | Press release
The Video Soundbox is a product for service operators. It has been developed with Dolby to become the first certified Dolby Atmos video / audio hub, delivering an immersive sound for all types of contents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005017/en/
Crafted and tuned by the world-renowned acoustic experts at Bang & Olufsen, Sagemcom Video Soundbox is equipped with a bespoke audio solution, the resulting sound is both natural and authentic, and the listening experience is as the artist originally intended it to be. With “Audio by Bang & Olufsen”, the Video Soundbox makes you feel what you’re hearing.
The great sound quality of the device is combined with its ability to access to best video and music contents, to grant the users a seamless access to a premium entertainment experience.
Thanks to optimal microphone implementation and performing noise cancellation system, the Video Soundbox offers accurate voice recognition that brings user-friendly far field voice control to access all contents:
- Premium 4K videos through linear channels and integrated streaming VOD services, such as Netflix, Amazon Prime Video and many others.
- Premium music with access to Spotify and Amazon Music, and more to come
- Integrated Voice Assistant, such as Amazon Alexa, to access news and traffic information, get sport results, book a trip and much more... with feedback on your TV set
The product includes Wi-Fi 6 technology to offer the best wireless connection with latest generation gateways including for 4K video streams.
After being the first manufacturer to integrate 4K technology, Sagemcom demonstrate with the Video Soundbox its ability to offer the latest technological breakthroughs to the telecom operators, enabling them to create a value proposition based on video service.
“The Video Soundbox allows to combine all services expected today by consumers in an all-in-one compact product, thanks to latest video, sound and voice services innovations developed with best-in-class partners. We are proud to launch the Video Soundbox, with first deployments this summer.”, said Olivier Taravel, Senior Executive Vice President, Audio Video Solutions Business Unit, Sagemcom.
About Sagemcom
Sagemcom is a French industrial group, world leader in high added-value communicating terminals and solutions for the broadband, audio video solutions and energy markets. Sagemcom designs, manufactures and supplies more than 40 million terminals around the world every year, using its own factories and industrial partners on all continents. The headcount of 5,500 employees works in more than 50 countries. Sagemcom has been profitable since its creation in 2008 and 31% of its capital belongs to its employees. In LBO since its 2008 carve-out with Safran, the Group entered its fourth LBO in 2019, with Charterhouse as major shareholder. The Group, which achieved a turnover of 2.1 billion euros in 2020, is led by a stable management team, the majority of whom have been at the helm of Sagemcom since 2008.
www.sagemcom.com // https://www.linkedin.com/company/sagemcom // https://www.instagram.com/sagemcom_inside // https://twitter.com/Sagemcom
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom